Literature DB >> 12441314

Taking aim at Ewing's sarcoma: is KIT a target and will imatinib work?

Brian J Druker.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12441314     DOI: 10.1093/jnci/94.22.1660

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  3 in total

1.  The effect of imatinib mesylate on the proliferation, invasive ability, and radiosensitivity of retinoblastoma cell lines.

Authors:  L R de Moura; J-C Marshall; S Di Cesare; B F Fernandes; E Antecka; M N Burnier
Journal:  Eye (Lond)       Date:  2012-11-16       Impact factor: 3.775

2.  ABT-869 inhibits the proliferation of Ewing Sarcoma cells and suppresses platelet-derived growth factor receptor beta and c-KIT signaling pathways.

Authors:  Alan K Ikeda; Dejah R Judelson; Noah Federman; Keith B Glaser; Elliot M Landaw; Christopher T Denny; Kathleen M Sakamoto
Journal:  Mol Cancer Ther       Date:  2010-03-02       Impact factor: 6.261

3.  The role of c-kit and imatinib mesylate in uveal melanoma.

Authors:  Patricia Rusa Pereira; Alexandre Nakao Odashiro; Jean Claude Marshall; Zelia Maria Correa; Rubens Belfort; Miguel N Burnier
Journal:  J Carcinog       Date:  2005-10-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.